Welcome to our dedicated page for Microbot Medical news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Medical stock.
Microbot Medical develops and distributes the LIBERTY Endovascular Robotic System, an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Company news centers on the system’s U.S. commercialization, adoption by healthcare institutions, use across peripheral endovascular case types, and clinical evidence from the ACCESS-PVI pivotal study.
Updates also cover medical-society guidance on radiation exposure and ergonomics in interventional radiology, conference presentations to healthcare and financial audiences, and commercial readiness outside the United States. The company frames LIBERTY around robotic vascular navigation and the need to address radiation exposure and physical strain for interventional teams.
Microbot Medical (Nasdaq: MBOT) will participate for the first time in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, March 16-19, 2026.
CEO Harel Gadot will present a live webcast on March 19 at 8:40 am ET highlighting LIBERTY® limited market release progress, clinical experience, and growth drivers ahead of a planned full market release at SIR in April 2026.
Microbot Medical (Nasdaq: MBOT) endorsed the American Medical Association’s late-2025 policy expanding protections against occupational ionizing radiation. The company highlights its LIBERTY Endovascular Robotic System as a safety solution: ACCESS-PVI showed a 92% relative reduction in radiation exposure. LIBERTY is FDA-cleared, single-use, remotely operated, entered a Limited Market Release in late 2025, and aims for a Full Market Release at SIR in April 2026.
The system also enables seated operation away from radiation, reducing reliance on heavy PPE and musculoskeletal strain for providers.
Microbot Medical (Nasdaq: MBOT) confirms no business disruption in the U.S. or Israel amid current geopolitical events and says employee safety is the top priority. The company says internal operations and its lead manufacturing partner remain fully functional, with sufficient U.S. inventory to support customers.
Following FDA clearance, Microbot began a limited market release of the LIBERTY Endovascular Robotic System in late 2025 and plans a full market release at the SIR conference in April 2026. The company is expanding U.S. commercial infrastructure with new sales hires and a Director of HEOR, and is building additional U.S. stock via a third-party logistics partner.
Microbot Medical (Nasdaq: MBOT) announced Tampa General Hospital is the first health system in Florida to adopt the LIBERTY® Endovascular Robotic System following the Company's recent FDA 510(k) clearance. The limited market release began in late 2025, with a planned full market release at the Society of Interventional Radiology conference in April 2026.
LIBERTY is described as the only FDA‑cleared, single‑use, remotely operated robotic system for peripheral endovascular procedures, aiming to improve navigation precision and reduce radiation and ergonomic strain.
Microbot Medical (Nasdaq: MBOT) announced that CEO Harel Gadot will be a featured panelist at The Surgical Disruptive Technology Summit during SAGES NBT Innovation Weekend, Feb 19-21, 2026, in Houston.
The session Endovascular Therapeutics: AI and Robotics will showcase the LIBERTY Endovascular Robotic System, its single-use remote operation, and planned full market release at SIR in April 2026.
Microbot Medical (NASDAQ: MBOT) highlighted its LIBERTY Endovascular Robotic System at the International Symposium on Endovascular Therapy (ISET), Feb 9-12, 2026, where experts discussed single-use robotic solutions.
The company noted LIBERTY's FDA clearance, limited market release begun in late 2025, cross-specialty hospital use, and plans for a full market release at SIR in April 2026.
Microbot Medical (NASDAQ: MBOT) will showcase the LIBERTY Endovascular Robotic System at the Society of Interventional Oncology meeting in Savannah, Feb 4-8, 2026. The company is in a limited market release started late 2025 and will give hands-on demos to accelerate adoption ahead of a planned full release in April 2026.
LIBERTY is FDA cleared as a single-use, remotely operated robotic system for peripheral endovascular procedures, designed to improve navigation and reduce radiation exposure and operator strain.
Microbot Medical (NASDAQ: MBOT) reported 2025 progress and set 2026 targets for its LIBERTY® Endovascular Robotic System. Key 2025 milestones include FDA 510(k) clearance, a Limited Market Release with Emory University Hospital as the first adopter, ACCESS PVI pivotal-trial data showing 100% robotic navigation success and a 92% reduction in radiation, plus 20 patents granted and 52 applications pending. The company plans a Full Market Release in Q2 2026 (aligned with SIR), aims to commercialize against a 2.5 million annual US procedure opportunity, expand global reach, and grow teleintervention and IP monetization efforts.
Microbot Medical (Nasdaq: MBOT) announced Emory University Hospital as the first hospital to adopt the LIBERTY Endovascular Robotic System for patient care, and a collaboration to establish an Endovascular Robotics Program in interventional radiology.
LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. The company commenced a limited market release and plans a full market release at the Society of Interventional Radiology conference in April 2026.
Microbot Medical (NASDAQ: MBOT) announced on Nov 5, 2025 that its LIBERTY® Endovascular Robotic System is now commercially available in the U.S. via a Limited Market Release focused on selected high‑procedure‑volume regions. The system is described as the first FDA‑cleared single‑use, remotely operated robotic system for peripheral endovascular procedures; the company received FDA 510(k) clearance in September. The LMR will collect real‑world feedback to guide responsible growth, supported by a newly hired core commercial team and a third‑party logistics partner. A Full Market Release is expected at the Society of Interventional Radiology meeting in April 2026.